Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China

Fineline Cube Dec 27, 2024

Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...

Company Drug

Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC

Fineline Cube Dec 27, 2024

China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...

Company Deals

Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition

Fineline Cube Dec 27, 2024

China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...

Company Deals Drug

Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery

Fineline Cube Dec 27, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...

Company Deals

AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy

Fineline Cube Dec 27, 2024

Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...

Company Drug

Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval

Fineline Cube Dec 27, 2024

China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...

Company Deals

Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories

Fineline Cube Dec 27, 2024

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...

Company Drug

Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study

Fineline Cube Dec 27, 2024

China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...

Company Drug

China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval

Fineline Cube Dec 27, 2024

On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...

Company Drug

Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)

Fineline Cube Dec 26, 2024

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...

Company Drug

Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval

Fineline Cube Dec 26, 2024

China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...

Company Drug

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis

Fineline Cube Dec 26, 2024

China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials

Fineline Cube Dec 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Drug

Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...

Company Drug

CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...

Company Drug

Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial

Fineline Cube Dec 26, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...

Company

Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District

Fineline Cube Dec 26, 2024

On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...

Company Drug

ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE

Fineline Cube Dec 26, 2024

China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local...

Company Deals

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors

Fineline Cube Dec 26, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...

Company Deals

Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment

Fineline Cube Dec 26, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...

Posts pagination

1 … 261 262 263 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.